---
figid: PMC5061806__BCP-82-1245-g002
figtitle: Targeting mTOR for neurodegenerative disorders
organisms:
- Saccharomyces cerevisiae
- Homo sapiens
pmcid: PMC5061806
filename: BCP-82-1245-g002.jpg
figlink: /pmc/articles/PMC5061806/figure/bcp12804-fig-0002/
number: F2
caption: Targeting mTOR for neurodegenerative disorders. The mechanistic target of
  rapamycin (mTOR) and the signalling pathways of phosphoinositide three‐kinase (PI
  3‐K), AMP activated protein kinase (AMPK), protein kinase B (Akt) and the hamartin
  (tuberous sclerosis 1)/tuberin (tuberous sclerosis 2) (TSC1/TSC2) complex are vital
  determinants of cell survival in the nervous system. mTOR governs programmed cell
  death pathways of apoptosis and autophagy that can affect stem cell development
  and maintenance, growth factors (erythropoietin (EPO), epidermal growth factor (EGF),
  fibroblast growth factor (FGF), brain derived neurotrophic growth factor (BDNF)),
  silent mating type information regulation two homologue one (Saccharomyces cerevisiae)
  (SIRT1), Wnt signalling, and Wnt1 inducible signalling pathway protein one (WISP1).
  Ultimately, mTOR signalling can impact the onset and progression of multiple disorders
  in the nervous system that include Alzheimer's disease (AD), Parkinson's disease
  (PD), Huntington's disease (HD), epilepsy, stroke and trauma
papertitle: Targeting molecules to medicine with mTOR, autophagy and neurodegenerative
  disorders.
reftext: Kenneth Maiese. Br J Clin Pharmacol. 2016 Nov;82(5):1245-1266.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7584296
figid_alias: PMC5061806__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5061806__F2
ndex: dbd32974-df2e-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5061806__BCP-82-1245-g002.html
  '@type': Dataset
  description: Targeting mTOR for neurodegenerative disorders. The mechanistic target
    of rapamycin (mTOR) and the signalling pathways of phosphoinositide three‐kinase
    (PI 3‐K), AMP activated protein kinase (AMPK), protein kinase B (Akt) and the
    hamartin (tuberous sclerosis 1)/tuberin (tuberous sclerosis 2) (TSC1/TSC2) complex
    are vital determinants of cell survival in the nervous system. mTOR governs programmed
    cell death pathways of apoptosis and autophagy that can affect stem cell development
    and maintenance, growth factors (erythropoietin (EPO), epidermal growth factor
    (EGF), fibroblast growth factor (FGF), brain derived neurotrophic growth factor
    (BDNF)), silent mating type information regulation two homologue one (Saccharomyces
    cerevisiae) (SIRT1), Wnt signalling, and Wnt1 inducible signalling pathway protein
    one (WISP1). Ultimately, mTOR signalling can impact the onset and progression
    of multiple disorders in the nervous system that include Alzheimer's disease (AD),
    Parkinson's disease (PD), Huntington's disease (HD), epilepsy, stroke and trauma
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - AKT1
  - AKT2
  - AKT3
  - TSC2
  - TSC1
  - CCL26
  - MTOR
  - EPO
  - TIMP1
  - EPX
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - BDNF
  - BDNF-AS
  - SIRT1
  - EGF
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - CCN4
  - Cancer
---
